|
_________________________ |
|
1 TREMFYA™ Product Monograph. Janssen Inc. November 10, 2017. |
|
2 Bachelez H. Interleukin 23 inhibitors for psoriasis: not just another number. Lancet 2017;390(10091):208-210. |
|
3 Blauvelt, A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 2017;76:405-417. |
|
4 Reich, K et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology. 2017;76:418-431. |
|
5 Canadian Dermatology Association. https://dermatology.ca/public-patients/skin/psoriasis/ (Accessed October 26, 2017). |
|
6 Rapp, S.R. et al. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology. 1999;41:401-407. |
